"Formoterol Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
| Descriptor ID |
D000068759
|
| MeSH Number(s) |
D02.033.100.291.425 D02.092.063.291.425
|
| Concept/Terms |
Formoterol Fumarate- Formoterol Fumarate
- Formoterol Fumarate, ((R*,R*)-(+-))-isomer
- 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate
|
Below are MeSH descriptors whose meaning is more general than "Formoterol Fumarate".
Below are MeSH descriptors whose meaning is more specific than "Formoterol Fumarate".
This graph shows the total number of publications written about "Formoterol Fumarate" by people in this website by year, and whether "Formoterol Fumarate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Formoterol Fumarate" by people in Profiles.
-
Trends in prescribing as-needed inhaled corticosteroid (ICS)-Formoterol for patients with asthma. Respir Med. 2023 02; 207:107096.
-
Mitochondrial biogenesis induced by the ?2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. Kidney Int. 2019 09; 96(3):656-673.
-
Proximal Tubule ?2-Adrenergic Receptor Mediates Formoterol-Induced Recovery of Mitochondrial and Renal Function after Ischemia-Reperfusion Injury. J Pharmacol Exp Ther. 2019 04; 369(1):173-180.
-
Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved ?2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury. J Neurotrauma. 2019 03 19; 36(6):962-972.
-
Association of Inhaled Corticosteroids and Long-Acting ?-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018 04 10; 319(14):1485-1496.
-
Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol. Sci Rep. 2017 09 05; 7(1):10578.
-
Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment. J Manag Care Spec Pharm. 2016 Mar; 22(3):293-304.
-
Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. 2015; 10:2055-66.
-
Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 Feb; 16(3):427-34.
-
Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury. J Am Soc Nephrol. 2014 Jun; 25(6):1157-62.